Edition:
United Kingdom

Caladrius Biosciences Inc (CLBS.OQ)

CLBS.OQ on NASDAQ Stock Exchange Capital Market

6.40USD
5:07pm BST
Change (% chg)

$-0.10 (-1.54%)
Prev Close
$6.50
Open
$6.65
Day's High
$6.75
Day's Low
$6.40
Volume
5,222
Avg. Vol
48,191
52-wk High
$11.65
52-wk Low
$2.65

Latest Key Developments (Source: Significant Developments)

Caladrius Biosciences Q2 Loss Per Share $0.42 From Continuing Operations
Thursday, 9 Aug 2018 

Caladrius Biosciences Inc ::CALADRIUS BIOSCIENCES REPORTS 2018 SECOND QUARTER AND FIRST SIX MONTHS FINANCIAL RESULTS.Q2 LOSS PER SHARE $0.42 FROM CONTINUING OPERATIONS.AS OF JUNE 30, 2018, CO HAD CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES OF $50.3 MILLION.  Full Article

Caladrius Biosciences Files For Mixed Shelf Of Upto $150 Mln
Tuesday, 24 Jul 2018 

July 24 (Reuters) - Caladrius Biosciences Inc ::CALADRIUS BIOSCIENCES INC FILES FOR MIXED SHELF OF UPTO $150 MILLION - SEC FILING.  Full Article

Caladrius Biosciences Announces Completion Of Enrollment Of Phase 2 T-Rex Clinical Trial Of CLBS03 For Type 1 Diabetes
Thursday, 18 Jan 2018 

Jan 18 (Reuters) - Caladrius Biosciences Inc ::CALADRIUS BIOSCIENCES ANNOUNCES COMPLETION OF ENROLLMENT OF PHASE 2 T-REX CLINICAL TRIAL OF CLBS03 FOR TYPE 1 DIABETES.CALADRIUS BIOSCIENCES INC - TOPLINE DATA FROM PRIMARY ENDPOINT OF COMPLETED STUDY ON CLBS03 EXPECTED IN EARLY 2019.  Full Article

Caladrius Biosciences reports 2017 third quarter results
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Caladrius Biosciences Inc :Caladrius Biosciences reports 2017 third quarter results.Q3 loss per share $0.38 from continuing operations.  Full Article

Caladrius Biosciences Q4 reports loss per share of $0.73
Friday, 17 Mar 2017 

Caladrius Biosciences Inc : Caladrius Biosciences announces 2016 fourth quarter and full year financial results . Q4 revenue rose 35 percent to $10.2 million . Q4 loss per share $0.73 .As of December 31, 2016, Caladrius had cash and cash equivalents of $14.7 million.  Full Article

Hitachi Chemical to buy remaining 80.1% interest in PCT from Caladrius
Thursday, 16 Mar 2017 

Hitachi Chemical Co Ltd <4217.T> :Hitachi chemical signs agreement to purchase from caladrius biosciences remaining 80.1% interest in percent for $75 million.  Full Article

BRIEF-Caladrius Biosciences Receives Sakigake Expedited Review Designation In Japan For CLBS12 For Treating Critical Limb Ischemia

* CALADRIUS BIOSCIENCES RECEIVES SAKIGAKE EXPEDITED REVIEW DESIGNATION IN JAPAN FOR CLBS12 FOR TREATING CRITICAL LIMB ISCHEMIA Source text for Eikon: Further company coverage: